Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04690660

Swiss Postpartum Hypertension Cohort

This open label, prospective observational, single-center registry is to study short-, intermediate-and long-term course of postpartum hypertension and predictors/risk factors associated with long term cardiovascular and renal risk.

Current disease management strategies will be evaluated.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Postpartum Hypertension (PPHT) Alzheimer Disease Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Dementia Female Urogenital Diseases and Pregnancy Complications Hypertension Hypertension, Pregnancy-Induced Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Pregnancy Complications Tauopathies Urogenital Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Medical Outpatient Department and Hypertension Clinic, University Hospital Basel

Basel, 4031, Switzerland

Location status: Recruiting

Location contact

Irene Hösli, Prof. Dr. med.

SUB_INVESTIGATOR

Michael Mayr, PD Dr. med.

SUB_INVESTIGATOR

Olav Lapaire, Prof. Dr. med.

SUB_INVESTIGATOR

Thenral Socrates, Dr. med.

CONTACT

[email protected]

+41 61 328 6647

Thenral Socrates, Dr. med.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • all women with hypertensive disorders of pregnancy
  • postpartum hypertension (blood pressure measurements of systolic ≥140 and/or diastolic ≥ 90mmHg or antihypertensive therapy within the first 14 days after delivery)
  • women with preexisting hypertension or
  • women on antihypertensive medication

Exclusion criteria

  • delivery > 14 days
  • lack of consent to participate in the study, language barriers or lack of general understanding

Treatment and study plan

Data collection for parameters of organ damage (cardiac and renal blood markers)

Other

Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.

Data collection for blood pressure (BP)

Other

Clinic blood pressure and 24hour BP Measurements

Home-based blood pressure management (substudy)

Other

Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.

Biomarker Profiles (substudy)

Other

Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).

Data collection on patient reported outcomes

Other

Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )

Primary outcomes

  1. Frequency of persistent hypertension defined by 24 hours BP measurement

    Time frame: through study completion, an average of 5 years

    Frequency of persistent hypertension defined by 24 hours BP measurement

  2. Frequency of persistent hypertension defined by office blood pressure measurement (OBPM, AOBPM)

    Time frame: through study completion, an average of 5 years

    Frequency of persistent hypertension defined by office blood pressure measurement (OBPM, AOBPM)

  3. Frequency of microalbuminuria

    Time frame: through study completion, an average of 5 years

    Frequency of microalbuminuria

  4. Frequency of damage to the retina of the eyes (retinopathy)

    Time frame: through study completion, an average of 5 years

    Frequency of damage to the retina of the eyes (retinopathy)

  5. Signs of hypertensive heart disease

    Time frame: up to 24 months

    Signs of hypertensive heart disease at transthoracic echocardiography determined by left ventricular hypertrophy (LVH)

  6. Frequency of dyslipidemia

    Time frame: through study completion, an average of 5 years

    Frequency of dyslipidemia

  7. Frequency of prediabetes/diabetes

    Time frame: through study completion, an average of 5 years

    Frequency of prediabetes/diabetes

Study contacts

Contact information is provided by the study sponsor or research team.

Thenral Socrates, Dr. med.

CONTACT

[email protected]

+41 61 328 6647

Thilo Burkard, Dr. med.

CONTACT

[email protected]

+41 61 328 7738

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Official study title

Swiss Postpartum Hypertension Cohort (Swiss-PPHT)

Important dates

Study start
2020
Primary completion
2030
Study completion
2030
First posted
Dec 31, 2020
Registry last updated
May 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.